You won't see many of these on the highway for a long Thanksgiving trip. You might see some on tow trucks or out of juice on the side of the highway. Why folks want to spend this much for a car that you cant take on a decent trip is beyond me. Seems like a fad or novelty for the wealthy.
oooooooooooohhhhh, I can hardly wait. Please please tell me what will happen. I always refer to the message boards for such valuable information. Please Amit, tell me what to do!!!
"we"??? who is that, the trailer full of @#$%%&@# 's living off a diet of old pizza and cheap beer?
$490 PT; Set at hold but very overvalued at current price. Price expected to fall
Better get in during afterhours or miss out. If you are foolish enough to be short, better cover now or you will lose it all on Monday! This is the new TESLA!!!!!
"I my babies need new shoes" ??????
Are you kidding me? Someone with your level of intelligence should not be investing. Good luck to you. Now we know who has driven this stock to unreasonable levels.
ViroPharma Drug Appeal Seen Driving 50% Return: Real M&A
By Brooke Sutherland - Sep 19, 2013 5:07 PM ET
ViroPharma Inc. (VPHM), the maker of drugs for rare diseases that rallied on optimism it will be the next biotechnology takeover target, could fetch a 50 percent premium in a deal.
The stock already surged as much as 34 percent to a 13-year high after Bloomberg News reported ViroPharma is working with Goldman Sachs (GS) Group Inc. on a possible auction and attracted interest from suitors including European drugmakers Sanofi and Shire Plc (SHP), citing people familiar with the process. JMP Group Inc. said the $2.6 billion seller of a treatment for hereditary angioedema, an inflammatory condition, could fetch $60 a share, compared with $40 yesterday.
Sanofi and Shire may be drawn by the chance to market ViroPharma’s drugs through existing salesforces and snap up the company’s pipeline while investors aren’t fully valuing its future revenue opportunities, said Oppenheimer Holdings Inc. and shareholder Penn Capital Management Co. Even after the gains, the Exton, Pennsylvania-based company traded yesterday at a lower multiple of projected sales than 87 percent of similar-sized U.S. peers, according to data compiled by Bloomberg.
“I’m certainly not surprised that they attracted interest,” Richard Simons, a Philadelphia-based analyst at Penn Capital, which oversees more than $7 billion including ViroPharma shares, said in a phone interview. “In terms of the pipeline, it’s very underappreciated. There are a lot of potential shots on goal that aren’t reflected in the stock.
Well, I happen to love the $500 memory foam mattress. Sleeps very comfortably and, like I said, feels just like a tempur-pedic. The mattress I purchased had much better reviews than the reviews the TPX beds were receiving. Maybe that is why TPX pulled customer reviews off their website. Hmmmmm.
Other consumers are wising up as well. No need to spend $4k when you can get a similar product for a fraction of the price. Sounds like you are trying to justify your expensive mattress purchase or an inflated stock price. Wonder which one?
Analysts Getting More Bullish On ViroPharma Following Friday's 28+% Surge On Takeover Chatter
Paul Quintaro, Benzinga Staff Writer
September 16, 2013 11:00 AM
ViroPharma (NASDAQ: VPHM) shares are up about three-quarters of a percent Monday morning on the heels of a 28-plus percent move higher on Friday. Traders in the name were responding to chatter the company had received offers from both Sanofi (NYSE: SNY) and Shire (NASDAQ: SHPG).
Monday morning numerous analysts are commenting and raising price targets on ViroPharma.
■Stifel Nicolaus raised target from $41 to $47, Buy rating maintained.
■Piper Jaffray target from $37 to $46, Overweight maintained.
■Oppenheimer target from $35 to $44, Outperform maintained.
■Mizuho sees value of $45 assuming cost savings if M&A does happen, believes could include a contingent value of $2-3/share related to cinryze.
Shire said to be interested in buying ViroPharma
Posted on: 16 Sep 2013 by Georgia Manors
London-listed drugmaker Shire is reported to be interested in buying ViroPharma.
ViroPharma, which produces drugs that treat rare diseases, has started working with Goldman Sachs on a possible auction and has attracted interest from a number of suitors, which also includes Sanofi, sources told Bloomberg.
Goldman Sachs has also sought out other suitors for the US drugmaker.
The news comes as a number of pharmaceutical firms turn to acquisitions in order to replace drugs which have patents expiring.
In August, Omgen agreed to buy Onyx Pharmaceuticals for $10.4bn, pushing the value of deals in the sector higher.
ViroPharma reported a 10% rise in second quarter sales to $103.7m, driven by its product Cinryze, which treats hereditary angioedema, an inflammatory condition.
Shire also produces Firazyr for hereditary angioedema, so an acquisition of ViroPharma would give the company a future value of $52 a share, according to Deutsche Bank.
Shares in Shire rose 2.38% to 2,536p at 13:30 on Monday while ViroPharma gained 2.22% to $39.13.
.... at overstock. feels just like the tempur-pedics I tried for $4,000. good luck with that. many other options available at a fraction of the price. I think people are wising up.